XERS News & Events

Reports Q1 revenue $83.1M, consensus $80.0M. "We are thrilled with our outstanding start to 2026, delivering first quarter net product revenue growth of 43%, reflecting the successful execution of our strategy," said John Shannon, CEO. "Recorlev was the standout performer, with net revenue nearly doubling year-over-year, driven by growth across our patient base and increased awareness across the prescriber base. Also in the quarter, we successfully completed the expansion of our commercial team, and we expect the impact of these targeted investments to become more evident in the second half of 2026 and beyond. Looking ahead, we remain confident in our ability to deliver on our full-year financial targets. Recorlev's strong Q1 and continued momentum gives us the confidence to raise the bottom end of our full year 2026 total revenue guidance. Our updated guidance of $380 million to $390 million represents more than 30% growth at the midpoint. Beyond our commercial execution, 2026 represents a pivotal year for our pipeline, with the anticipated Phase 3 initiation of XP-8121 later in the year marking a significant value creation inflection point. Our strong financial foundation enables us to advance these strategic priorities while creating sustainable long-term value for shareholders."

Sees FY26 adjusted EBITDA to increase in total dollars compared to FY25. "Our exceptional results in 2025 reflect the strength of our business and set the stage for our future," said Steve Pieper, CFO. "As we look ahead to 2026, we will build on the strong momentum across our enterprise and expect total revenue to range from approximately $375 million to $390 million, representing more than 30% growth at the midpoint. This outlook will further strengthen our balance sheet, which will create even more financial flexibility to drive value in both the near and long term."

Reports Q4 revenue $85.81M vs. $60.1M last year. "Thanks to the entire Xeris organization, 2025 was a transformational year, marked by focused execution, record revenue growth, and our emergence as a self-funding, sustainable biopharmaceutical company," said John Shannon, CEO. "As we enter 2026 from this position of strength, we remain focused on driving continued rapid revenue growth, the timely execution of XP-8121's ongoing development leading into the start of its Phase 3 clinical trial, and the judicious deployment of capital to further strengthen our business outlook in order to maximize long-term value for shareholders."

Xeris Biopharma's subsidiaries Xeris Pharmaceuticals and Strongbridge Dublin have filed a patent infringement lawsuit under the Hatch-Waxman Act related to Recorlev in the U.S. District Court for the District of New Jersey against Torrent Pharmaceuticals and Somerset Therapeutics, each of which filed an Abbreviated New Drug Application, or ANDA, with the FDA seeking approval to manufacture, use or sell a generic version of Recorlev. Xeris's complaint seeks an injunction to prevent the manufacture, use, and sale of a generic version of Recorlev by each ANDA Filer until the expiration of Xeris's patents in March 2040. Each ANDA Filer alleged that the four patents covering Recorlev that are listed in the FDA's "Approved Drug Products with Therapeutic Equivalence Evaluations", scheduled to expire in March 2040, are invalid, unenforceable, or will not be infringed by the respective ANDA Filer's commercial manufacture, use, or sale of the generic levoketoconazole product described in its ANDA submission. Xeris intends to enforce and defend its intellectual property rights relating to Recorlev.